Valo Health Public Company (Nasdaq:KVSA)

Primary contact

🚀 Merged with Khosla Ventures Acquisition Co. on June 9, 2021. in a SPAC deal worth $2.8B, raising $750M in the process.
Valo Health is on a mission to transform the drug discovery and development process using human-centric data and AI computation. As a digitally native company, Valo aims to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company's Opal Computational Platform consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Aside from its headquarters in Boston, MA, Valo also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT.
Primary contact

Funding 💰

Total $400M
Select investors Koch Disruptive Technologies, PSP Investments, Longevity Vision Fund, Mirae Asset Ventures, Atinum Investment
Last update: September 4, 2021